Physician profile
Steven P Heddinger
NPI 1750344743
$3,090.43
in general payments reported to CMS, 2019-2025
47 companies · $576 in 2025
The $576 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $329 · 2021: $69.53 · 2022: $342 · 2023: $534 · 2024: $575 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630 · Education: $54.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,630.31 |
| Education | $54.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $402.07 | 2019-2025 | Darzalex, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $162.25 | 2019-2025 | Enhertu, Tagrisso |
| Abbvie INC. | $158.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $143.71 | 2019-2025 | |
| Genentech USA, INC. | $133.61 | 2019-2025 | Polivy, Venclexta, Columvi |
| Alexion Pharmaceuticals, INC. | $127.64 | 2019-2025 | Ultomiris |
| Pfizer INC. | $109.66 | 2019-2025 | |
| Exelixis INC. | $102.90 | 2019-2025 | Cabometyx |
| Daiichi Sankyo INC. | $102.21 | 2022-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $96.56 | 2019-2025 | Keytruda, Lynparza |
| Amgen INC. | $96.09 | 2019-2023 | Xgeva, Nplate, Vectibix |
| Lilly USA, LLC | $87.77 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Eisai INC. | $86.30 | 2020-2025 | |
| Celgene Corporation | $82.86 | 2019-2024 | Reblozyl |
| Astellas Pharma US INC | $76.18 | 2019-2025 | Vyloy, Padcev |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Heddinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.